



Arisha Patel, MD, MBA, MSHA, MSc

Precision Oncologist · Physician-Scientist · Founder and CEO

hello@arishapatelmd.com · arishapatelmd.com · linkedin.com/in/arishapatelmd

Profile

Triple board-certified Medical Oncologist, Hematologist, and Internist and physician-scientist working at the intersection of precision oncology, machine learning, and care delivery. Fellowship-trained at the NCI-designated UPMC Hillman Cancer Center, with an MBA in Biomedical Entrepreneurship and AI in Healthcare from Carnegie Mellon University. Former Senior Medical Director of Personalized Healthcare at Genentech, where she led medical strategy for the tumor-agnostic MyPathway basket trial and helped move biomarker-driven therapy into clinical practice. Founder and CEO of BioNuture and BioSynova, building precision oncology for the years before a cancer diagnosis and the decades after treatment.

Board Certification

Diplomate, American Board of Internal Medicine: Internal Medicine (2017), Medical Oncology (2021), Hematology (2025)

Education and Training

Master of Business Administration, Biomedical Entrepreneurship Track

2017 to 2020 · Tepper School of Business, Carnegie Mellon University

Leadership Development Certification, Accelerate Leadership Center, Tepper School of Business

Postdoctoral Fellowship, NIH T32 Entrepreneurial Research Training Program

2017 to 2019 · University of Pittsburgh

Fellowship, Hematology-Oncology

2016 to 2019 · UPMC Hillman Cancer Center (NCI-Designated Comprehensive Cancer Center), University of Pittsburgh Medical Center

Certification, Big Data and Healthcare Analytics: A Path to Personalized Medicine

2016 · Department of Biomedical Informatics, University of Pittsburgh Medical Center

Residency, Internal Medicine

2014 to 2016 · University of Pittsburgh Medical Center

Doctor of Medicine

2011 to 2014 · Chicago Medical School, Rosalind Franklin University of Medicine and Science

Master of Science, Healthcare Administration and Management

2009 to 2011 · Rosalind Franklin University of Medicine and Science

Master of Science, Biological Sciences

2009 to 2010 · Rosalind Franklin University of Medicine and Science

Bachelor of Science, Biology (Minors: Chemistry, Psychology)

2002 to 2006 · Southern Methodist University

Academic Appointments

Adjunct Clinical Instructor, Divisions of Oncology and Hematology

2020 to 2022 · Stanford University School of Medicine

Professional Experience

Founder and Chief Executive Officer, BioNurture

2022 to present

Founded and lead a concierge, physician-led oncology and hematology practice built for the phases of cancer care the acute system overlooks: risk stratification and surveillance before diagnosis, and longitudinal support through survivorship. Board-certified specialist care paired with coordinated synthesis of labs, imaging, and biomarkers into a single clinical plan. Designed a membership model with defined stabilization, optimization, and graduation pathways that return patients to independent stewardship of their health.

Founder and Chief Executive Officer, BioSynova

2022 to present

Founded the clinical intelligence and infrastructure company underlying BioNurture, holding the intellectual property, clinical decision support, and operational architecture for longitudinal oncology and hematology care. Developing the Cancer Resilience Index, a longitudinal measure of cancer risk now in research validation. Built on the principle that AI in oncology should augment clinical judgment and reduce fragmentation, never replace the physician.

Senior Medical Director, Personalized Healthcare, Genentech, Inc. (Roche Group)

2019 to 2021

Medical Director for MyPathway (NCT02091141), an industry-sponsored, tumor-agnostic, open-label Phase 2a basket trial spanning molecularly targeted and immuno-oncology agents. Led scientific and medical strategy, steering committee and advisory board meetings with external key opinion leaders, and regulatory consultation. Work supported two NCCN Category 2A recommendations for pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer and salivary gland tumors. Developed medical strategy for external control arms using real-world data and machine learning, and co-led biomarker-testing coverage and policy initiatives.

Hematologist and Oncologist, Clinical Practice

2020 to 2024

Provided hematology and oncology care across community and academic cancer centers nationally.

Peer-Reviewed Publications

- Patel A, et al. Pertuzumab plus trastuzumab for treatment-refractory HER2-amplified metastatic colorectal cancer: comparison of the MyPathway trial with a real-world external control arm. JCO Clinical Cancer Informatics. 2022 Jun.
- Patel A, et al. Natural history of HER2-amplified and HER2 wild-type refractory metastatic colorectal cancer in US clinical practice. JCO Clinical Cancer Informatics. 2022 Mar.

- Patel A, et al. Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, Phase 2a multiple basket study. Cancer Discovery. 2021 Dec.
- Javle M, Patel A, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, Phase 2a, multiple basket study. Lancet Oncology. 2021 Sep;22(9):1290 to 1300.
- Patel A, et al. Machine-learning algorithms for predicting hospital readmissions in sickle cell disease. British Journal of Haematology. 2020 Nov.
- Patel A, et al. Outcomes of patients with acute myeloid leukemia who relapse after five years of complete remission. Oncology Research. 2020 Aug.
- Patel A, et al. The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States. Cancer. 2017 Aug.

Selected Abstracts and Presentations

- Patel A, et al. An innovative approach to alleviating fatigue in metastatic breast cancer patients. Clinical Cancer Research (AACR). 2025; Abstract P4-01-01.
- Meric-Bernstam F, Patel A, et al. MyPathway HER2 basket study: pertuzumab plus trastuzumab treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. Journal of Clinical Oncology. 2021;39(15_suppl):3004. Oral Late-Breaking Abstract, ASCO Annual Meeting.
- Patel A, et al. Efficacy of atezolizumab in solid tumors with high tumor mutational burden (TMB): a MyPathway study cohort. Cancer Research. 2021; AACR Abstract LB012.
- Patel A, et al. Machine learning algorithms in predicting hospital readmissions in sickle cell disease. Blood. 2019;134(Suppl 1):982. 61st ASH Annual Meeting, Orlando, FL.

Professional Service

Board Member, The Board of Medicine, 2022 to present

Professional Memberships

- American Society of Clinical Oncology (ASCO), 2016 to present
- American Society of Hematology (ASH), 2016 to present
- European Society for Medical Oncology (ESMO), 2019 to present
- American Association for Cancer Research (AACR), 2019 to present

Writing

The Cancer Resilience Code, essays and podcast on predictive cancer care, survivorship, AI in medicine, and the business of care delivery.